Evolus, Inc. (EOLS) Stock

Evolus, Inc. (EOLS) is a Healthcare stock trading at $6.61 (as of 2026-06-18), with a market capitalization of $432.01M and a trailing P/E of -10.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Evolus, Inc. develops and sells medical aesthetic products in the United States for physicians and their patients. Its Jeuveau product is a purified botulinum toxin type A formulation (900 kilodaltons) used for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; the company is headquartered in Newport Beach, California and was incorporated in 2012.

Valuation — source: SEC EDGAR (first-party)
Price	$6.61
Market Cap	$432.01M
P/E Ratio	-10.0
EV / EBITDA	-33.8
Price / Book	-15.17
Price / Sales	1.45
DCF Value (model)	$-13.38
DCF Upside vs Price	-302.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$297.18M
Net Margin	-17.4%
Return on Equity	150.9%
Debt / Equity	-5.43
Current Ratio	2.04
Revenue Growth (YoY)	11.6%
EPS Growth (YoY)	-1.2%
FCF Growth (YoY)	134.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.86 (distress)
Piotroski F-Score	2/9 (weak)

Valuation vs Sector & Industry
Stock P/E	-10.0
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-148.1%
vs Industry	-159.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Nantahala Capital Management, LLC ($26.21M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	David Moatazedi
Employees	372
Country	US
IPO Date	2018-02-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.